Prefilled Syringes Market Growth Outlook: CAGR of 5.6% and Value Reaching USD 10.51 Billion by 2032 | Braun SE, GSK plc.

Prefilled Syringes Market is estimated to valued at USD 7.18 Bn in 2025 and is expected to reach USD 10.51 Bn in 2032, exhibiting CAGR of5.6% from 2025 to 2032

BURLINGAME, CA, UNITED STATES, November 24, 2025 /EINPresswire.com/ -- The Global Prefilled Syringes Market is gaining traction as demand rises in chronic disease management, vaccine delivery, and biologics. Prefilled syringes offer better patient safety by reducing dosing errors, simplify administration, and are more convenient, especially in self-injection and home-care settings. Innovation in syringe materials and manufacturing — such as advanced glass and polymer designs — is further propelling their adoption across hospitals, clinics, and home care.

Request a sample report at: https://www.coherentmarketinsights.com/insight/request-sample/162

Global Prefilled Syringes Market Key Takeaways

According to Coherent Market Insights (CMI), the global prefilled syringes market size is estimated to reach USD 7.18 Bn in 2025 and is expected to grow at a CAGR of 5.6% during the forecast period, totaling USD 10.51 Bn by 2032.

Glass remains the most popular material for prefilled syringe manufacturing due to its excellent drug compatibility and superior barrier properties.

Based on drug type, biologics segment is slated to account for 38.5% of the global prefilled syringes market share in 2025.

Demand is anticipated to remain high for staked in-needle prefilled syringes, owing to their simplicity and wide application.

Disposable prefilled syringes are expected to dominate the market due to their advantages in infection control, convenience, and regulatory compliance.

North America is projected to dominate the global prefilled syringes industry, holding a share of 42. 2% in 2025.

Asia Pacific is poised to become one of the fastest-growing markets for prefilled syringes, owing to expanding patient pool, increasing adoption of self-administration therapies, and growing healthcare infrastructure.

Rising Prevalence of Chronic Diseases Fueling Prefilled Syringes Market Growth

The global prefilled syringes market is expected to grow steadily during the forecast period. This is mostly due to increasing prevalence of chronic diseases, growing preference for self-administration drugs, and advancements in injectable drug delivery technologies.

There is a spike in cases of chronic conditions like diabetes, cancer, autoimmune disorders, and cardiovascular diseases. Acording to the International Diabetes Federation, about 589 million adults are living with diabetes globally. This number is likely to rise to 853 million by 2050.

This escalating burden of chronic diseases is expected to fuel demand for prefilled syringes during the forecast period. These syringes are particularly suited to long-term disease management because of their ease of use, accuracy, safety, and other advantages.

Prefilled syringes offer precise dosing, reduced risk of contamination, and convenience for patients. This makes them increasingly preferred for self-administration and clinical use. For example, insulin for diabetes is often delivered via prefilled syringes, which offer precision and convenience.

Request for Customization: https://www.coherentmarketinsights.com/insight/request-customization/162

High Costs, Product Recalls, and Alternative Delivery Systems Limiting Growth

The global prefilled syringes market outlook appears promising, considering the high prevalence of chronic diseases and growing demand for injectable drugs. However, high costs, product recalls, and growing competition from alternative drug delivery systems might limit market growth to some extent during the forecast period.

Prefilled syringes are often more expensive than traditional formats as their production requires specialized aseptic filling lines, cleanrooms, quality control, and validation. This high cost especially hinders adoption in price-sensitive or developing markets.

There has also been an increase in prefilled syringe recalls in recent years. For instance, Sun Pharmaceutical Industries recently recalled over 24,00 prefilled syringes of Fyremadel (ganirelix acetate) injection due to presence of particulate matter. Such product recalls damage trust among healthcare providers and patients.

Another growth limiting factor is the rising popularity of alternative drug delivery technologies. There is an increasing competition from auto-injectors, wearable injectors, and other advanced drug delivery technologies. This could reduce overall prefilled syringes market demand during the forecast period.

Growth of Biologics and Biosimilars Unlocking Growth Prospects

Rising adoption of biologics and biosimilars is creating strong tailwinds for the prefilled syringes market. Biopharmaceuticals and biosimilars are becoming more common in the contemporary world. For instance, according to Coherent Market Insights’ latest analysis, global demand for biologics is forecast to rise at a CAGR of 10.6% between 2025 and 2032.

As more injectable biopharmaceuticals such as monoclonal antibodies and vaccines become available, demand for safe, accurate, and user-friendly delivery systems is rising. Prefilled syringes reduce dosing errors, minimize contamination, and support self-administration.

With biosimilars gaining ground globally, pharmaceutical companies are likely to favour reliable delivery formats such as prefilled syringes. This is expected to create a favorable environment for the prefilled syringes market expansion during the forecast period.

Emerging Prefilled Syringes Market Trends

Shift from vial-based medications to prefilled syringes is a key growth-shaping trend in the market. There is a growing trend toward patients self-injecting at home, which boosts demand for patient-friendly prefilled syringes. Rising need for improved patient compliance is also boosting sales of prefilled syringes.

Increasing demand for self-administration is supporting market expansion. Both healthcare professionals and patients in the contemporary world prefer prefilled syringes for improved safety, dosing accuracy, and enhanced patient compliance. Prefilled syringes help minimize dosing errors and reduce contamination risk, which improves safety. They also help in reducing needlestick injuries and are more convenient than traditional vial + syringe systems.

Growing popularity of home healthcare is fueling prefilled syringe demand. The convenience, safety, and dosing accuracy of prefilled syringes make them especially attractive for home-based care.

Rising use of prefilled syringes in vaccines and immunization programs is also boosting prefilled syringes market value. These syringes simplify mass administration, ensure accurate dosing, and maintain vaccine potency.

Innovations in drug delivery technologies are enhancing the safety, convenience, and efficacy of prefilled injectables. Companies are developing innovative prefilled injections with ergonomic designs for self-administration and user-friendly handling. For instance, they are introducing novel prefilled insulin syringes for diabetic patients. Similarly, cyclic olefin polymers (COP) polymer syringes are growing in popularity due to their various advantages.

Competitor Insights

Key companies in prefilled syringes market report:

Becton, Dickinson and Company
Gerresheimer AG
West Pharmaceutical Services, Inc.
Nipro Europe Group Companies
Terumo Corporation
Braun SE
GSK plc.
Sanofi
Pfizer Inc.
Polymedicure
Amsino International, Inc.
Bayer AG
Leeford Healthcare Limited
Stevanato Group S.p.A.
Regeneron Pharmaceuticals Inc.
Ypsomed AG
SOL-Millennium
Stevanato Group S.p.A.
Torrent Pharmaceuticals Ltd.
Key Developments

In October 2025, Polpharma Biologics launched Ranivisio PFS (ranibizumab biosimilar pre-filled syringe) in Europe. This is Europe’s first ranibizumab biosimilar in a pre-filled syringe and aims to provide more affordable biologic treatment in ophthalmology.

In April 2025, the U.S. FDA approved a prefilled syringe version of Argenx’s VYVGART Hytrulo for treating immune disorders. This new option allows patients to self-inject the drug at home, making treatment more convenient.

In July 2025, the U.S. FDA approved GSK’s Shingrix vaccine in a prefilled syringe format for the prevention of shingles. This novel presentation makes it convenient for healthcare providers to store and administer the vaccine.

In January 2025, SCHOTT Pharma launched next generation polymer syringe system called SCHOTT TOPPAC. This new product is designed to improve safety, efficiency, and sustainability in healthcare.

Buy The Latest Version Of the Reports with an Impressive Discount (Up to 25% Off ) at:

https://www.coherentmarketinsights.com/insight/buy-now/162

Author of this Marketing PR:

Alice Mutum is a seasoned senior content editor at Coherent Market Insights, leveraging extensive expertise gained from her previous role as a content writer. With seven years in content development, Alice masterfully employs SEO best practices and cutting-edge digital marketing strategies to craft high-ranking, impactful content. As an editor, she meticulously ensures flawless grammar and punctuation, precise data accuracy, and perfect alignment with audience needs in every research report. Alice's dedication to excellence and her strategic approach to content make her an invaluable asset in the world of market insights.

About CMI:

Coherent Market Insights leads into data and analytics, audience measurement, consumer behaviors, and market trend analysis. From shorter dispatch to in-depth insights, CMI has exceled in offering research, analytics, and consumer-focused shifts for nearly a decade. With cutting-edge syndicated tools and custom-made research services, we empower businesses to move in the direction of growth. We are multifunctional in our work scope and have 450+ seasoned consultants, analysts, and researchers across 26+ industries spread out in 32+ countries.

Raj Shah
Coherent Market Insights Pvt. Ltd.
+1 252-477-1362
email us here
Visit us on social media:
LinkedIn
Instagram
Facebook
X

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.